[An overview of the management of erectile disorders].
The large successive studies on the treatment of erectile disorders started with local injections of papaverine in 1982, followed by the marketing of intracavernous injections of alprostadil in 1994 and, in 1998, sildenafil, the first type 5 phosphodiesterase inhibitor. An efficient alternative to improve the quality and duration of an erection is presently represented by intra-cavernous injections of alprostadil alfadex when oral treatments are insufficient, inefficient or contraindicated.